RDDA:F:F-Dr. Reddy's Laboratories Limited (EUR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 68

Change

-2.00 (-2.86)%

Market Cap

USD 59.15B

Volume

50.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MRKC:F MERCK KGAA NAM.SP.ADR

-0.60 (-1.95%)

USD 68.55B
MRK:F Merck & Company Inc

-1.65 (-1.08%)

USD 67.36B
H6D0:F Haleon PLC

-0.08 (-1.84%)

USD 41.60B
TKDA:F Takeda Pharmaceutical Company ..

+0.20 (+1.61%)

USD 41.17B
H6D:F Haleon PLC

-0.10 (-1.12%)

USD 40.82B
TEV:F Teva Pharmaceutical Industries..

+0.20 (+1.18%)

USD 19.32B
3KY:F HANSOH PHARMAC. HD-00001

-0.26 (-11.11%)

USD 15.54B
SH0:F Shionogi & Co. Ltd

-1.30 (-9.35%)

USD 10.96B
NB3:F Neurocrine Biosciences Inc

+0.80 (+0.75%)

USD 10.71B
0C8:F Catalent Inc

-0.18 (-0.33%)

USD 9.81B

ETFs Containing RDDA:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.68% 59% D- 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.68% 59% D- 62% D
Trailing 12 Months  
Capital Gain 12.40% 58% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.40% 58% F 54% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 5.55% 69% C- 58% F
Dividend Return 6.37% 63% D 53% F
Total Return 0.82% 33% F 30% F
Risk Return Profile  
Volatility (Standard Deviation) 13.54% 91% A- 81% B-
Risk Adjusted Return 47.07% 77% C+ 66% D+
Market Capitalization 59.15B 99% N/A 97% N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.